Effects of lamivudine on outcome after liver resection for hepatocellular carcinoma in patients with active replication of hepatitis B virus

Hepatology Research

Volumn 37, Issue 2, 2007, Pages 94-100

  Kubo, Shoji ^a   Tanaka, Hiromu ^a   Takemura, Shigekazu ^a   Yamamoto, Satoshi ^a   Hai, Seikan ^a   Ichikawa, Tsuyoshi ^a   Kodai, Shintaro ^a   Shinkawa, Hiroji ^a   Sakaguchi, Hiroki ^a   Tamori, Akihiro ^a   Habu, Daiki ^a   Nishiguchi, Shuhei ^b  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

Adefovir dipivoxil; Hepatitis B virus; Hepatocellular carcinoma; Lamivudine; Liver resection; YMDD mutant virus

Indexed keywords

ADEFOVIR DIPIVOXIL; ALANINE AMINOTRANSFERASE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; INTERFERON; LAMIVUDINE; VIRUS DNA;

ADULT; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DISEASE FREE SURVIVAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HISTOPATHOLOGY; HUMAN; LIVER CELL CARCINOMA; LIVER RESECTION; MALE; MULTIVARIATE ANALYSIS; POSTOPERATIVE CARE; PRIORITY JOURNAL; RECURRENCE RISK; RISK FACTOR; TREATMENT OUTCOME; UNIVARIATE ANALYSIS; VIRUS MUTANT; VIRUS REPLICATION;

EID: 33947154931     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2007.00013.x     Document Type: Article

References (36)

1. Kubo S, Hirohashi K, Tanaka H et al. Effect of viral status on recurrence after liver resection for patients with hepatitis B virus-related hepatocellular carcinoma. Cancer 2000; 88: 1016-24.
2. Kubo S, Hirohashi K, Tanaka H et al. Virologic and biochemical changes and prognosis after liver resection for hepatitis B virus-related hepatocellular carcinoma. Dig Surg 2001; 18: 26-33.
3. Dienstag JL, Perrillo RP, Schiff ER et al. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995; 333: 1657-61.
4. Nevens F, Main J, Honkoop P et al. Lamivudine therapy for chronic hepatitis B: A six-month randomized dose-ranging study. Gastroenterology 1997; 113: 1258-63.
5. Lai CL, Chien RN, Leung NW et al. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998; 339: 61-8.
6. Leung NW, Lai CL, Chang TT et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: Results after 3 years of therapy. Hepatology 2001; 33: 1527-32.
7. Dienstag JL, Goldin RD, Heathcote EJ et al. Histological outcome during long-term lamivudine therapy. Gastroenterology 2003; 124: 105-17.
8. Ohkoshi S, Ogata N, Ichida T. The long-term clinical outcome of 1-year treatment of chronic hepatitis B with lamivudine -5 years observation. Hepatol Res 2003; 27: 13-17.
9. Chayama K, Suzuki Y, Kobayashi M et al. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy. Hepatology 1998; 27: 1711-16.
10. Lok AS, Hussain M, Cursano C et al. Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen-negative patients receiving lamivudine therapy. Hepatology 2000; 32: 1145-53.
11. Fujioka S, Shimomura H. Two cases of chronic hepatitis B with emergence of lamivudine-resistant virus during long-term therapy. Hepatol Res 1999; 12: 97-104.
12. Liaw YF, Sung JJY, Chow WC et al. Lamivudine for patients with chronic hepatitis B and advanced disease. N Engl J Med 2004; 351: 1521-31.
13. Matsumoto A, Tanaka E, Rokuhara A et al. Efficacy of lamivudine for preventing hepatocellular carcinoma in chronic hepatitis B: A multicenter retrospective study of 2795 patients. Hepatol Res 2005; 32: 173-84.
14. Kubo S, Hirohashi K, Tanaka H et al. Usefulness of viral concentration measurement by transcription-mediated amplification and hybridization protection as a prognostic factor for recurrence after resection of hepatitis B virus-related hepatocellular carcinoma. Hepatol Res 2003; 25: 71-7.
15. Sakugawa H, Nakasone H, Nakayoshi T et al. Correlation between serum transaminase activity and virus load among patients with chronic liver disease type B. Hepatol Res 2001; 21: 159-68.
16. Yuen MF, Sablon E, Hui CK, Yuan HJ, Decraemer H, Lai CL. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology 2001; 34: 785-91.
17. Lok AS, Zoulim F, Locarnini S et al. Monitoring drug resistance in chronic hepatitis B virus (HBV)-infected patients during lamivudine therapy: Evaluation of performance of INNO-LiPA HBV DR assay. J Clin Microbiol 2002; 40: 3729-34.
18. Edmondson HA, Steiner PE. Primary carcinoma of the liver: A study of 100 cases among 48 900 necropsies. Cancer 1954; 7: 462-503.
19. Liver Cancer Study Group of Japan. Classification of Primary Liver Cancer, 1st English edn. Tokyo: Kanehara, 1997.
20. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: Diagnosis, grading and staging. Hepatology 1994; 19: 1513-20.
21. Pugh RNH, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60: 646-9.
22. UICC. Liver. In: Spiessl B, Beahrs OH, Hermanek P et al. eds. TMN Atlas: illustrated guide to the YNM/pTNM classification of malignant tumours, 3rd edn. Berlin: Springer-Verlag, 1992; 104-111.
23. Liaw YF, Tai DI, Chu CM, Chen TJ. The development of cirrhosis in patients with chronic type B hepatitis: A prospective study. Hepatology 1988; 8: 493-6.
24. Lok AS, Lai CL. Acute exacerbations in Chinese patients with chronic hepatitis B virus (HBV) infection: Incidence, predisposing factors and etiology. J Hepatol 1990; 10: 29-34.
25. Tang B, Kruger WD, Chen G et al. Hepatitis B viremia is associated with increased risk of hepatocellular carcinoma in chronic carriers. J Med Virol 2004; 72: 35-40.
26. Volpes R, van den Oord JJ, Desmet VJ. Vascular adhesion molecules in acute and chronic liver inflammation. Hepatology 1992; 15: 269-75.
27. Andreone P, Gramenzi A, Cursaro C et al. High risk of hepatocellular carcinoma in anti-HBe positive liver cirrhosis patients developing lamivudine resistance. J Viral Hepat 2004; 11: 439-42.
28. Di marco V, Di Stefano R, Ferraro D et al. HBV-DNA suppression and disease course in HBV cirrhosis patients on long-term lamivudine therapy. Antivir Ther 2005; 10: 431-9.
29. Ikeda K, Saitoh S, Suzuki Y et al. Interferon decreases hepatocellular carcinogenesis in patients with cirrhosis caused by the hepatitis B virus: A pilot study. Cancer 1998; 82: 827-35.
30. Lin SM, Sheen IS, Chien RN, Chu CM, Liaw YF. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology 1999; 29: 971-5.
31. Papatheodoridis GV, Manesis E, Hadziyannis SJ. The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis. J Hepatol 2001; 34: 306-13.
32. van Zonneveld M, Honkoop P, Hansen BE et al. Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B. Hepatology 2004; 39: 804-10.
33. Yuen MF, Hui CK, Cheng CC et al. Long-term follow-up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection: The effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications. Hepatology 2001; 34: 139-45.
34. Lampertico P, Del Ninno E, Vigano M et al. Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy. Hepatology 2003; 37: 756-63.
35. Sun HC, Tang ZY, Wang L et al. Postoperative interferon α treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma: A randomized clinical trial. J Cancer Res Clin Oncol 2006; 132: 458-65.
36. Colombo M, Donato MF. Prevention of hepatocellular carcinoma. Semin Liver Dis 2005; 25: 155-61.